![]() |
Antiplatelet Use Following Acute Coronary Syndromes...
September 1, 2012 - Clinical , Featured By: Addolorata Ciccone, Co-Copy Editor – Acute Coronary Syndromes Acute coronary syndrome (ACS) is a myocardial ischemia caused by obstruction of coronary arteries. ACS is stratified into three types, based on electrocardiogram (EKG) changes and the presence of cardiac biomarkers (e.g. troponin, creatinine phosphokinase, and myoglobin). To guide treatment plans, it is important to identify… |
![]() |
Brilinta® vs. Plavix® in Patients with Acute Coronary...
February 1, 2012 - Clinical , Featured By: Ronik Saha, Pharm.D. Candidate c/o 2013 – Clopidogrel (Plavix®) is a thienopyridine antiplatelet agent, which exerts its antiplatelet effects via in vivo conversion to an active thiol metabolite that irreversibly blocks the P2Y-12 component of platelet ADP receptors. This prevents activation of the GP2B/3A complex, thereby preventing platelet aggregation. Along with aspirin, clopidogrel reduces… |